real-time news and commentary for investors
Wednesday, Oct 2
Upbeat comments from Wedbush on eye surgery drug send Omeros higher — again
- Wedbush's Liana Moussatos is out predicting a March 2014 PDUFA date and a July 2014 U.S. launch date for Omeros' (OMER +15%) OMS302.
- A little color from Moussatos: "Given the stellar clinical results from both Phase 3 trials, we do not anticipate any delays and expect a first pass approval."
- The analyst hasn't been shy about expressing a bullish opinion on OMER. Indeed it was Moussatos' September 16 call (doubling U.S. penetration estimates for OMS302) that sent the shares soaring more than 50%.
- Price target raised to $32 from $28.